# US 2021/0275439 A1 · Fluticasone and vilanterol formulation and inhaler

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275439 A1
- Document ID: US20210275439A1
- Status: Published application
- Kind: A1
- Application number: 17/059,617
- Filed: 2019-06-05
- Published: 2021-09-09
- Earliest claimed: 2018-06-07
- Assignees: Kindeva Drug Delivery L.P.
- Applicants: Kindeva Drug Delivery L.P.
- Inventors: Sarah J. Dexter; Philip M. Cocks
- Web page: https://patentgrep.com/patent/US20210275439A1

## CPC

- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 31/02: Halogenated hydrocarbons
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 33/16: Fluorine compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A composition comprising particulate fluticasone or a pharmaceutically acceptable salt or solvate thereof, particulate vilanterol or a pharmaceutically acceptable salt or solvate thereof, and 1,1-difluoroethane.

## Claims

### Claim 1

A composition comprising:
particulate fluticasone or a pharmaceutically acceptable salt or solvate thereof;
particulate vilanterol or a pharmaceutically acceptable salt or solvate thereof; and
1,1-difluoroethane (HFA-152a).

### Claim 2 (depends on 1)

The composition of claim 1, wherein the fluticasone or a pharmaceutically acceptable salt or solvate thereof is fluticasone furoate.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the vilanterol or a pharmaceutically acceptable salt or solvate thereof is vilanterol trifenatate.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the propellant consists essentially of 1,1-difluoroethane (HFA-152a).

### Claim 5 (depends on 1)

The composition of claim 1 contained in a canister, wherein the size of the fluticasone particles in the canister is between about 2 micrometers and 4 micrometers.

### Claim 6 (depends on 1)

The composition of claim 1 contained in a canister, wherein the size of the vilanterol trifenatate particles in the canister is between about 1 micrometer and 2 micrometers.

### Claim at position 7

7-9. (canceled)

### Claim 10

A composition comprising
particulate fluticasone or a pharmaceutically acceptable salt or solvate thereof;
particulate vilanterol or a pharmaceutically acceptable salt or solvate thereof; and
1,1-difluoroethane (HFA-152a), wherein fluticasone and vilanterol or the pharmaceutically acceptable salts or solvates thereof are the only active medicaments in the composition.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the fluticasone or a pharmaceutically acceptable salt or solvate thereof is fluticasone furoate.

### Claim 12

(canceled)

### Claim 13 (depends on 10)

The composition of claim 10, wherein the propellant consists essentially of 1,1-difluoroethane (HFA-152a).

### Claim 14 (depends on 10)

The composition of claim 10 contained in a canister, wherein the size of the fluticasone particles in the canister is between about 2 micrometers and 4 micrometers.

### Claim 15 (depends on 10)

The composition of claim 10 contained in a canister, wherein the size of the vilanterol trifenatate particles in the canister is between about 1 micrometer and 2 micrometers.

### Claim at position 14

16-18. (canceled)

### Claim 19 (depends on 1)

An aerosol canister comprising the composition of claim 1.

### Claim 20 (depends on 19)

The aerosol canister of claim 19 comprising at least one surface having a primer composition comprising a silane having two or more reactive silane groups separated by an organic linker group disposed thereon, wherein the primer composition has a coating composition comprising an at least partially fluorinated compound disposed thereon.

### Claim 21

(canceled)

### Claim 22 (depends on 20)

The aerosol canister of claim 20, wherein the at least one surface is at least a portion of a valve surface.

### Claim 23 (depends on 1)

An inhaler comprising the composition of claim 1.

### Claim 24 (depends on 10)

An aerosol canister comprising the composition of claim 10.

### Claim 25 (depends on 25)

The aerosol canister of claim 25 comprising at least one surface having a primer composition comprising a silane having two or more reactive silane groups separated by an organic linker group disposed thereon, wherein the primer composition has a coating composition comprising an at least partially fluorinated compound disposed thereon.

### Claim 26 (depends on 25)

The aerosol canister of claim 25, wherein the at least partially fluorinated compound is a polyfluoropolyether silane.

### Claim 27 (depends on 10)

An inhaler comprising the composition of claim 10.

### Claim 28 (depends on 19)

An inhaler comprising the aerosol canister of claim 19.
